Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

Point Loma woman donates wheelchair to L.A. fire victim, honoring late husband; Woman's husband received wheelchair from ABC ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company with a market capitalization of $40.39 million, has announced a strategic partnership with Zina ...